MeSH term
Frequency | Condition_Probility | Humans | 95 | 0.0 |
Mitosis/*physiology | 3 | 3.0 |
Phosphorylation | 21 | 0.0 |
Research Support, Non-U.S. Gov't | 65 | 0.0 |
Tumor Cells, Cultured | 20 | 0.0 |
Cell Cycle | 5 | 0.0 |
*DNA Damage | 2 | 0.0 |
Dose-Response Relationship, Radiation | 2 | 0.0 |
Hydroxyurea/pharmacology | 2 | 3.0 |
Ultraviolet Rays | 4 | 0.0 |
Aged | 12 | 0.0 |
Cell Cycle/physiology | 7 | 2.0 |
Cell Cycle Proteins/*metabolism | 12 | 3.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Male | 17 | 0.0 |
Middle Aged | 15 | 0.0 |
Prognosis | 6 | 0.0 |
cdc25 Phosphatase/*metabolism | 9 | 23.0 |
Adult | 8 | 0.0 |
Aged, 80 and over | 8 | 0.0 |
Female | 23 | 0.0 |
Immunohistochemistry | 16 | 0.0 |
Treatment Outcome | 2 | 0.0 |
Animals | 25 | 0.0 |
Cell Cycle Proteins/metabolism | 8 | 2.0 |
DNA Damage | 5 | 0.0 |
*G2 Phase | 2 | 5.0 |
*Mitosis | 6 | 4.0 |
Signal Transduction | 5 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 2 | 0.0 |
Esophagus/metabolism/pathology | 2 | 28.0 |
*Gene Expression Profiling | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 5 | 0.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
RNA, Neoplasm/genetics/metabolism | 2 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 12 | 0.0 |
Acetyltransferases/metabolism | 2 | 2.0 |
Cell Line | 8 | 0.0 |
Cyclin D1/metabolism | 2 | 1.0 |
Rats | 4 | 0.0 |
Receptors, Estrogen/metabolism | 2 | 0.0 |
Receptors, Progesterone/metabolism | 2 | 1.0 |
Receptors, Steroid/*metabolism | 2 | 3.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 27 | 0.0 |
Trans-Activators/metabolism | 2 | 0.0 |
Cell Cycle Proteins/*biosynthesis/genetics | 3 | 18.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
cdc25 Phosphatase/*biosynthesis/genetics | 2 | 66.0 |
Age Factors | 2 | 0.0 |
Cell Cycle Proteins/*biosynthesis | 4 | 9.0 |
Time Factors | 8 | 0.0 |
cdc25 Phosphatase/*biosynthesis | 4 | 100.0 |
Cell Division | 6 | 0.0 |
Cyclin-Dependent Kinases/metabolism | 3 | 0.0 |
Mice | 14 | 0.0 |
Mice, Transgenic | 5 | 0.0 |
S Phase | 3 | 0.0 |
Transfection | 8 | 0.0 |
CDC2 Protein Kinase/*metabolism | 7 | 6.0 |
Mitosis/*genetics | 2 | 5.0 |
Molecular Weight | 2 | 0.0 |
Blotting, Western | 9 | 0.0 |
Cell Cycle Proteins/genetics/*metabolism | 7 | 5.0 |
Comparative Study | 5 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
RNA, Messenger/metabolism | 8 | 0.0 |
RNA, Neoplasm/analysis | 2 | 0.0 |
cdc25 Phosphatase/genetics/*metabolism | 3 | 18.0 |
14-3-3 Proteins | 7 | 5.0 |
Binding Sites | 2 | 0.0 |
Cell Cycle Proteins/chemistry/genetics/*metabolism | 2 | 7.0 |
Cyclins/metabolism | 2 | 0.0 |
G2 Phase | 3 | 1.0 |
Hela Cells | 22 | 0.0 |
Mutation | 8 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
cdc25 Phosphatase/chemistry/genetics/*metabolism | 2 | 40.0 |
English Abstract | 4 | 0.0 |
Base Sequence | 7 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Amino Acid Sequence | 7 | 0.0 |
Hamsters | 2 | 0.0 |
Isomerism | 2 | 0.0 |
Molecular Sequence Data | 10 | 0.0 |
Protein Binding | 5 | 0.0 |
Serine/metabolism | 4 | 1.0 |
*CDC2-CDC28 Kinases | 3 | 0.0 |
*Cell Cycle Proteins | 3 | 0.0 |
Cyclin A/*metabolism | 3 | 7.0 |
Cyclin-Dependent Kinases/*metabolism | 4 | 1.0 |
Enzyme Activation | 6 | 0.0 |
G2 Phase/*physiology | 4 | 26.0 |
Protein-Serine-Threonine Kinases/*metabolism | 3 | 0.0 |
CDC2 Protein Kinase/metabolism | 4 | 2.0 |
Cell Cycle Proteins/biosynthesis/genetics/*physiology | 2 | 40.0 |
Gene Expression | 7 | 0.0 |
*Cell Cycle | 2 | 0.0 |
Cell Cycle Proteins/*analysis | 2 | 11.0 |
Multivariate Analysis | 2 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
Survival Rate | 2 | 0.0 |
cdc25 Phosphatase/*analysis | 2 | 100.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Cell Cycle/*drug effects | 4 | 2.0 |
Cell Division/drug effects | 10 | 0.0 |
Biopsy | 2 | 0.0 |
Cyclin B/biosynthesis | 2 | 20.0 |
Cyclin D1/biosynthesis | 2 | 4.0 |
Cytoplasm/metabolism | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
Ki-67 Antigen/biosynthesis | 3 | 3.0 |
cdc25 Phosphatase/biosynthesis/*metabolism | 2 | 100.0 |
*Tyrosine 3-Monooxygenase | 3 | 6.0 |
cdc25 Phosphatase/*antagonists & inhibitors | 2 | 28.0 |
*Nuclear Proteins | 3 | 0.0 |
Cyclin B/*metabolism | 2 | 6.0 |
Blotting, Northern | 4 | 0.0 |
Caspases/metabolism | 2 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Flow Cytometry | 4 | 0.0 |
Tumor Markers, Biological/biosynthesis | 2 | 5.0 |
Catalysis | 2 | 0.0 |
Cell Cycle/*physiology | 4 | 1.0 |
Cell Cycle/drug effects | 3 | 0.0 |
Cell Cycle Proteins/*antagonists & inhibitors | 2 | 33.0 |
Substrate Specificity | 2 | 0.0 |
Isoenzymes/*genetics | 2 | 0.0 |
cdc25 Phosphatase | 13 | 27.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
Genetic Vectors | 2 | 0.0 |
*cdc25 Phosphatase | 16 | 33.0 |
G1 Phase/physiology | 3 | 4.0 |
Interphase | 2 | 1.0 |
Microinjections | 4 | 1.0 |
Phosphoprotein Phosphatase/genetics/*metabolism | 4 | 22.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
Phosphoprotein Phosphatase/metabolism | 3 | 4.0 |
Protein-Tyrosine-Phosphatase/*genetics | 2 | 1.0 |
Cysteine Endopeptidases/*metabolism | 2 | 0.0 |
Mitosis | 2 | 0.0 |
Multienzyme Complexes/*metabolism | 2 | 1.0 |
Phosphoprotein Phosphatase/*metabolism | 5 | 5.0 |
Proteasome Endopeptidase Complex | 2 | 0.0 |
cdc25 Phosphatase/metabolism | 5 | 9.0 |
Protein-Tyrosine-Phosphatase/*metabolism | 2 | 1.0 |
Proto-Oncogene Proteins c-myc/*metabolism | 2 | 2.0 |
In Vitro | 2 | 0.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
Protein-Tyrosine-Phosphatase/metabolism | 2 | 1.0 |
Protein Kinases/*metabolism | 2 | 0.0 |
Antineoplastic Agents/pharmacology | 3 | 0.0 |
Cell Line, Tumor | 2 | 0.0 |
Mice, Nude | 2 | 0.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Apoptosis/*drug effects | 2 | 0.0 |
Isothiocyanates/*pharmacology | 2 | 28.0 |
Protein Transport | 2 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 2 | 0.0 |
Chromosome Mapping | 2 | 0.0 |
Proteins/metabolism | 2 | 0.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Cell Cycle Proteins/*genetics | 2 | 1.0 |
Phosphoprotein Phosphatase/*genetics | 2 | 5.0 |
Sequence Alignment | 3 | 0.0 |
Carcinogens/pharmacology | 2 | 2.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 2 | 0.0 |
In Situ Hybridization | 4 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Genes, Dominant | 2 | 0.0 |
Cell Differentiation/drug effects | 2 | 0.0 |
Dimerization | 2 | 0.0 |
Cells, Cultured | 4 | 0.0 |
Mice, Inbred BALB C | 3 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Cytoplasm/chemistry | 3 | 1.0 |
Proteins/*physiology | 2 | 1.0 |
Multigene Family | 2 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Point Mutation | 3 | 0.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Up-Regulation | 2 | 0.0 |
Cell Cycle Proteins/genetics/metabolism | 2 | 2.0 |
Apoptosis/drug effects/*genetics/radiation effects | 2 | 66.0 |
Protein-Serine-Threonine Kinases/*genetics | 2 | 0.0 |
U937 Cells | 2 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
